Summary

• The company cannot recommend any practices, procedures or usage that deviate from the approved labeling.
• The recommended dose of STELARA for adult patients with active psoriatic arthritis (PsA) is 45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks. For patients with coexistent moderate-to-severe plaque psoriasis weighing more than 100 kg, the recommended dose is 90 mg administered subcutaneously initially and 4 weeks later, followed by 90 mg administered subcutaneously every 12 weeks.¹
• There is no data available regarding the dosing of STELARA more frequently than every 12 weeks during the maintenance period in adult patients with active PsA.

LITERATURE SEARCH

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) conducted on 11 June 2024 did not identify any relevant citations pertaining to this topic.